There is no distinct explanation of the mechanism for the prepartal prostaglandin F2alpha (PGF2alpha) increase in pregnant dogs. Although the PGF2alpha-synthase (PGFS [AKR1C3]) mRNA expression and localization profiles have been previously investigated in canine utero/placental compartments, the availability and biochemical activity of the PGFS (AKR1C3) protein remain unknown. In order to better understand the regulation of canine uterine PGF2alpha availability and eventual prepartum release in luteolytic amounts in dogs, canine-specific PGFS (AKR1C3) and 15-hydroxyprostaglandin dehydrogenase (HPGD) antibodies were generated and used to characterize the expression, cellular localization, and biochemical properties of PGFS (AKR1C3) and HPGD in the utero/placental compartments and corpus luteum throughout pregnancy and at prepartum luteolysis. PGFS (AKR1C3) expression was weak or absent in luteal samples. Uterine PGFS (AKR1C3) was up-regulated postimplantation and declined prepartum. The utero/placental expression of PGFS (AKR1C3) was identified in the superficial uterine glands throughout gestation and in the trophoblast cells within the feto-maternal contact zone during placentation, suggesting a possible role for PGFS (AKR1C3) in the trophoblast invasion. Utero-placental HPGD was up-regulated until postimplantation, lower at midgestation, and greatly suppressed at prepartum. Expression was routinely identified in the endometrial surface and glandular epithelia, and positive signals were also observed in the trophoblast cells at the feto-maternal contact zone. The biochemical activity of recombinant PGFS (AKR1C3) and HPGD was confirmed after its expression in a heterologous system. The colocalization of HPGD with PGFS (AKR1C3) expression suggests a modulatory role for HPGD as a gatekeeper of the supply of prostaglandin in the pregnant canine uterus.
INTRODUCTION
Domestic dogs are monestrous, predominantly nonseasonal breeders, having an obligatory anestrus period of variable length (mean 5 mo in most breeds) following a gestational or a nonpregnant luteal phase of approximately 2 mo, with interestrus intervals (anestrus) and progesterone (P4) profiles being similar in pregnant and nonpregnant bitches except for an abrupt prepartum luteolysis that terminates pregnancy. P4 of luteal origin is required throughout pregnancy, and corpora lutea (CL) are the only significant source of P4 (reviewed in [1, 2] ).
Plasma P4 levels are maximal by Day 20-25 of the luteal phase and decline progressively until concentrations ,1 ng/ml are reached by Day 60-90 in nonpregnant dogs, signaling the onset of anestrus [3] , or until prepartum luteolysis at Day 62-64.
When used in high doses and repeated treatments, exogenous prostaglandin F2alpha (PGF2alpha) can be luteolytic. In contrast, however, to the livestock, there are no known extraluteal luteolytic factors involved in slow luteal regression of nonpregnant bitches, and luteal function is normal following hysterectomy [4] . In contrast, locally produced prostaglandins appear to contribute to the paracrine/autocrine regulation of CL formation rather than towards luteolysis [5, 6] . The slow luteal regression observed in nonpregnant bitches appears to be a passive degenerative CL-aging process that also appears to occur in midpregnancy (reviewed in [1, 2] ). In contrast, the dramatic drop in P4 approximately 24-48 h before parturition involves an acute prepartum luteolysis associated with a large increase in the PGF2alpha-metabolite (13,14-dihydro-15keto-PGF2alpha; PGFM), in maternal plasma [7, 8] . The latter implies a direct role of PGF2alpha during prepartum luteolysis and/or fetal expulsion. Prepartum PGF2alpha release may originate in the fetal part of the placenta because canine fetal trophoblast cells were observed to have up-regulated expression of prostaglandin-endoperoxide synthase 2 (PTGS2), i.e., cyclooxygenase 2 (COX2) [9] . That origin is also suggested by the observation in dogs that antigestagen blockage of P4 receptor results in an up-regulation of PTGS2 in the utero/ placental compartment, predominantly in the fetal trophoblast [9] . Assuming that PTGS2 is the rate-limiting factor, the placental prostaglandin synthesis system appears to be strongly activated at the time of the prepartum increase in PGF2alpha output. This agrees with the conclusion of Luz et al. [10] that the placenta is the main source of the luteolytic PGF2alpha increase.
Recently, the canine PGF2a-synthase (PGFS) cDNA sequence was cloned [5] . Based on very high homology with isoforms isolated from other species, it has been classified as aldo-keto reductase family 1, member C3 (AKR1C3), has received the GenBank accession number NM_001012344, and is the only canine-specific PGFS isoform known to date. When PGFS (AKR1C3) mRNA-expression profiles were examined throughout pregnancy [9] , the highest expression in the utero/ placental compartments was observed during postimplantation and midgestation, followed by a prepartum decline at time of the PGF2alpha increase in peripheral blood. We therefore proposed that posttranscriptional regulation and enhanced substrate turnover, because of the elevated availability of PTGS2, might be important factors in elevating PGF2alpha at prepartum [9] , although data on PGFS (AKR1C3) expression at the protein level were unavailable because of lack of caninespecific and/or cross-reacting antibodies. Consequently, no final conclusions could be drawn.
In the present study, PGFS (AKR1C3) expression was localized via specific antibodies and quantified during pregnancy and prepartum. Because the cloned canine PGFS (AKR1C3) is a member of the aldo-keto reductase family, which includes a number of closely related enzymes sharing a very high (over 80%) mRNA and protein homology, the aforementioned data on the mRNA expression profiles need to be treated cautiously until the biochemical properties and substrate specificity of the PGFS (AKR1C3) protein in the conversion of PGH2 to PGF2alpha is elucidated. Therefore, the biochemical properties of the heterogeneously expressed recombinant canine PGFS (AKR1C3) and 15-hydroxyprostaglandin dehydrogenase (HPGD) proteins were tested on their specific substrates as part of the present study.
The availability of prostaglandins can be regulated by changes in HPGD, an enzyme that catabolizes PGE2 and PGF2alpha to their inactive metabolites PGFM and 13,14-dihydro-15-keto PGE2 (PGEM) [11, 12] .
HPGD has been cloned from tissues of several species, e.g., cattle, mouse, human, sheep, horse, and rat [13] [14] [15] [16] [17] [18] , but there are no available data on the expression and regulation of HPGD in reproductive tissues of the dog. A potential increase in PGF2alpha metabolism by HPGD could explain the low PGFM levels detected in peripheral plasma at the time of increased placental PGFS (AKR1C3) mRNA expression, and conversely, a decrease in bioavailability of HPGD prior to parturition might facilitate the increased output of PGF2alpha into the peripheral blood at that time. We therefore generated and validated canine-specific anti-PGFS (AKR1C3) and HPGD antibodies, and applied them to identify changes in expression within the CL and utero/placental compartments during canine pregnancy and especially prepartum.
MATERIALS AND METHODS

Animals, Tissue Sampling, and Preservation
All experiments were conducted in accordance with animal welfare legislation. Eighteen crossbred, healthy bitches, aged 2-8 yr, were used for this study. Four groups were created with dogs ovariohysterectomized according to the following schedule: The day of mating was recorded as Day 0 for all bitches. In the preimplantation group, pregnancies were confirmed by uterine flushings. The time of prepartum luteolysis was detected by measuring P4 levels at 6-h intervals from Day 58 of pregnancy onwards. When a steep P4 decline (below 3 ng/ml) was detected in three consecutive measurements, females were subjected to ovariohysterectomy.
Classified as placenta endotheliochorialis, zonaria [19, 20] , canine placenta starts to form immediately after implantation on Days 17-18 after mating. Among its most unique characteristics are the strong invasion of fetal trophoblast, development of marginal hematoma, and developing of glandular chambers. The latter are also called the ''spongy zone.'' They grow out of the superficial endometrial glands and form a 1-2-mm thick layer between the placental labyrinth and the connective tissue covering the deep endometrial glands. They develop mostly during the first half of pregnancy and reach their maximal size around Day 40 of gestation. From then on the fully developed utero/placental units are established [19] .
Following this, the postimplantation and midgestation groups used in our study relate to periods of canine gestation characterized by the formation of and the presence of the fully developed utero/placental compartments, respectively.
Immediately after surgery the CL, uterine samples (preimplantation) and utero/placental compartments (full thickness, middle part of the girdle avoiding the marginal hematoma) were collected. For immunohistochemistry (IHC) and in situ hybridization (ISH), immediately after surgery, tissue samples were trimmed of surrounding connective tissues and fixed in 10% neutral phosphate buffered formalin for 24 h at þ48C. Afterwards, tissue samples were washed with PBS that was frequently changed during 1 wk, dehydrated in a graded ethanol series, and embedded in paraffin-equivalent Histo-Comp (Vogel).
For RNA preservation and Western blot analyses, samples were immediately soaked in RNAlater (Ambion Biotechnology GmbH) and incubated for 24 h at þ48C. For long-term storage tissue samples were held at À808C.
As already published in [9] , where tissue material from the same animals was used, the following average P4 concentrations were measured in peripheral blood plasma by radioimmunoassay at the respective periods of pregnancy: 35.71 6 7.9 ng/ml at the preimplantation period, 29.73 6 13.23 ng/ml at postimplantation, 13.32 6 8.66 ng/ml at midgestation, and 2.07 6 0.99 ng/ml during the prepartum luteolysis.
RNA Isolation, Reverse Transcription, and Homology Cloning of Canine-Specific HPGD Total RNA was isolated from utero/placental compartments and CL using Trizol reagent according to the manufacturer's instructions (Invitrogen). The RNA content was measured with a SmartSpec Plus spectrophotometer (BioRad Laboratories, Inc.). Prior to reverse transcription (RT), in order to remove genomic DNA contamination, DNAse treatment with RQ1 RNase-free DNase (Promega) was performed following the manufacturer's protocols. Subsequently, applying our previously published protocol [6] and using random hexamers as primers, cDNA was synthesized with RT reagents purchased from Applied Biosystems. Between 100 and 200 ng of DNase-treated total RNA was used for each sample in RT reactions carried out in an Eppendorf Mastercycler. The RT-PCR conditions were as follows: 8 min at 218C, 15 min at 428C, then the reaction was stopped by incubation for 5 min at 998C.
The canine-specific HPGD cDNA sequence had not been characterized prior to our study. Hence, molecular cloning and sequencing became prerequisites in order to obtain the anticipated data on the mRNA level. Based on the alignment of the known HPGD homologues with an online available canine genomic sequence, the following primers flanking the predicted open reading frame (ORF) of canine HPGD were chosen and ordered from Microsynth AG: forward: 5 0 -ATG CAC GTG AAC GGC AAA GT-3 0 and reverse: 5 0 -CTG AGT TTT TGC ATG AAA TG-3 0 . The GeneAmp Gold RNA PCR Kit from Applied Biosystems was applied as described previously [6] for the hot-start PCR reaction. The annealing temperature was 588C. Using the RNA isolated from canine CL and utero/placental compartments of at least three dogs, PCR products comprising 801 bp of canine HPGD ORF coding for 267 amino acids were successfully amplified. The subsequent cloning procedure consisted of separating PCR products on a 2% ethidium bromidestained agarose gel, extracting them using the Qiaex II gel extraction system (Qiagen GmbH), subcloning into the pGEM-T vector (Promega), transforming and amplifying in XL1 Blue competent cells (Stratagene), purifying bacterial plasmids with the PureYield Plasmid Midiprep System (Promega) and finally sequencing on both strands with T7 and Sp6 primers (Microsynth). Subsequently, the cloned sequence was submitted to GenBank with accession number JQ407019: Canis lupus familiaris 15-hydroxyprostaglandin dehydrogenase mRNA, complete cds. ChromasPro Version 1.2 oligo software (Technelysium Pty. Ltd.) was used for prediction of the amino acid sequence.
Real-Time (TaqMan) PCR
Semiquantification of HPGD mRNA expression in the utero/placental compartments and CL throughout pregnancy was performed by means of realtime (TaqMan) PCR analysis using an automated fluorometer ABI PRISM 7500 Sequence Detection System (Applied Biosystems). Each sample was quantified in duplicate using 96-well optical plates (Applied Biosystems).
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The DNase treatment and cDNA synthesis were as for qualitative PCR and as described above. For negative controls, autoclaved water instead of cDNA and the so-called minus RT control were used. The reaction mixtures of 25 ll were prepared as follows: 200 nM TaqMan Probe, 300 nM of each primer, 12.5 ll Fast Start Universal Probe Master (ROX) (Roche Diagnostics), and 5 ll cDNA, corresponding to 100 nm total RNA per sample in duplicate. The amplification conditions were denaturation at 958C for 10 min, 40 cycles at 958C for 15 sec, and 608C for 60 sec. The semiquantitation of HPGD mRNA expression was obtained by using three reference genes, GAPDH, 18SrRNA, and cyclophilin, in the comparative CT method (DDCT method) according to the manufacturer's protocols for the ABI 7500 Fast Real-Time PCR System and as described previously [6, 21] . The CT slope method was applied for measurement of the efficiency of the PCR assays that were established to ensure approximately 100% reaction efficiency. Primers and 6-carboxyfluorescein-and 6-carboxytetramethyl-rhodamine-labeled TaqMan probes were designed using Primer Express Software ( 0 (GenBank accession number FJ797658); length of the amplicons was 125 bp. A commercially available canine-specific cyclophilin A TaqMan system was purchased from Applied Biosystems (product no. Cf03986523-gH).
Construction of Expression Plasmids
The PGFS (AKR1C3)-and HPGD-expression plasmids were cloned by means of Gateway cloning technology (Invitrogen) following the manufacturer's protocol. The templates used were canine-specific sequences of PGFS (AKR1C3) (GenBank accession number NM_001012344) [5] and the freshly cloned HPGD sequence (GenBank accession number JQ407019). In the first step, attB sequences were added to PGFS (AKR1C3) and HPGD forward and reverse primers for generating PGFS (AKR1C3) and HPGD ORF-encoding PCR products flanked by attB recognition sites for BP recombination. Stop codons were omitted in the reverse primers to generate templates for the subsequent cloning procedure of fusion proteins expressing constructs; regions of gene-specific sequence are underlined:
attB1-PGFS (AKR1C3) forward: 5 0 -GGG GAC AAG TTT GTA CAA AAA AGC AGG CTT AAT GAA TCT AAT GAA ACT TAG-3 The reaction mixture was prepared as follows: 12.5 ll water, 10 ll 53 Phusion HF Buffer, 200 lM dNTP mix, 0.5 lM forward primer sense, 0.5 lM reverse primer, 5% dimethyl sulfoxide, 0.75 M betaine (Sigma-Aldrich Chemie GmbH), 1 U Phusion High-Fidelity DNA Hot Start Polymerase, and 25 mM MgCl 2 (New England Biolabs). Amplification conditions were initial denaturation at 988C for 1 min, followed by 34 cycles at 988C for 10 sec, 508C for 20 sec, 728C for 30 sec, and final elongation at 728C for 5 min. Reactions were carried out in an Eppendorf Mastercycler. After separation at 100 V on an ethidium bromide-stained 1% agarose gel, PCR products were purified using the Qiaex II gel extraction system according to the manufacturer's instructions. Afterwards, following the Gateway system manufacturer's protocol, BP recombination was performed using the BP clonase II between an attB-flanked cDNA fragment and attP-containing pDONR221 vector to produce an entry clone. The entry clone was transformed in One Shot ccdB Survival 2 T1R Competent Cells (Invitrogen). Subsequently, bacteria were plated onto LB-Agar plates containing 50 lg/ml kanamycin (Sigma-Aldrich). This was followed by isolation of entry clones using a PureYield Plasmid Miniprep system and control restriction digestion. In the next step, LR recombination was performed with pHSV-EYFP-Rfc-C1 and pHSV-V5His-Rfc-C1 expression vectors [22] in order to generate plasmids expressing the enhanced yellow fluorescent protein (EYFP) and His-tagged canine-specific PGFS (AKR1C3) and HPGD fusion proteins. The LR recombination was performed between the entry clone's attL sites and attR sites existing in the expressing vectors, using LR clonase II (Invitrogen). Afterwards, plasmids were transformed into One Shot ccdB Survival 2 T1R Competent Cells and plated on LB-Agar plates containing 100 lg/ml ampicillin (Sigma-Aldrich). Purification of plasmids with PureYield Plasmid Miniprep, control restriction digestion, and subsequent sequencing on both strands (Microsynth) of plasmids expressing recombinant canine PGFS (AKR1C3)-3 with the utero/placental sample (Ut/PL) from the midgestation period of pregnancy (approximately 34-36 kDa); proteins were stained with the caninespecific anti-PGFS (AKR1C3) antibody. Nontransfected Vero 2.2 cells were used as a negative control. b-actin (45 kDa) served as an internal loading control. E) The epitope-specific blocking peptide was used in order to quench the PGFS (AKR1C3)-specific signal in a Ut/PL sample derived from midgestation period of pregnancy. Representative immunoblots are shown. 
GRAM ET AL.
and HPGD-, His-, and EYFP-tagged fusion proteins completed the cloning procedure. Finally, the plasmids were amplified and isolated using the Plasmid Maxi Kit from Qiagen according to the manufacturer's instructions.
Cell Cultures and Transient Expression
The Vero 2.2-cell line was used as a heterologous system and was cultured in Dulbecco modified Eagle Medium-high glucose (PAA) with 2 mM Lglutamine including 2% fetal bovine serum (PAA) and 1% penicillinstreptomycin (PAA). Prior to transfection, cells were seeded into 100-mm Petri dishes. After the Vero 2.2 cells reached 80% confluency, transfection was performed with pHSV-EYFP-Rfc-C1-PGFS (AKR1C3) or -HPGD and pHSVV5His-Rfc-C1-PGFS (AKR1C3) or -HPGD expression vectors to produce recombinant canine EYFP-and His-tagged PGFS (AKR1C3) and HPGD fusion proteins. The FuGENE HD-transfection reagent (Roche Diagnostics) was used according to the manufacturer's protocol in 3 ml serum-containing medium at a ratio of 1 lg DNA to 3.5 ll reagent, in complexes that were incubated at room temperature for at least 25 min in 100 ll serum-free medium. Subsequently, cells were incubated at 378C in humidified air containing 5% CO 2 . Six hours after transfection, the medium was changed and cell culture was continued for another 24 h. Transfection efficiency was assessed by monitoring the cellular expression of EYFP-tagged PGFS (AKR1C3) and HPGD proteins under a fluorescent microscope. For harvesting, cells were rinsed with ice-cold PBS and lysed using 300 ll of NET-2 lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 0.05% NP-40) containing 10 ll/ml protease inhibitor cocktail (Sigma Aldrich).
Purification and Assessment of Biochemical Activities of PGFS (AKR1C3)-and HPGD-His-Coupled Recombinant Canine Proteins
Canine recombinant His-tagged PGFS (AKR1C3) and HPGD proteins were expressed in Vero 2.2 cells and purified with Ni-NTA (nickel-nitrilotriacetic acid) Magnetic Agarose Beads (Qiagen) following the manufacturer's protocol. Protein concentration was measured by a Bradford assay using the SmartSpec Plus spectrophotometer. Activity of recombinant His-tagged PGFS (AKR1C3) protein was initiated by adding 100 lM NADPH (Sigma Aldrich) to 100 ll of mixtures containing 1 lg recombinant purified canine PGFS (AKR1C3)-His, 50 mM Tris HCl pH 7.5, and 10-30 lM PGH2. For assessment of HPGD-His activity, reactions were initiated by adding 1 lM NAD þ (Sigma Aldrich); 10-30 lM PGE2 or PGF2alpha were used as substrates. All experiments were repeated at least three times. For negative controls, no recombinant proteins were used, and the resulting background signals were subtracted from the values obtained for samples in which recombinant proteins were used. Reactions were run at 378C for 1-10 min and finally heat inactivated for 5 min. The conversions of PGH2 into PGF2alpha and PGE2, of PGF2alpha into PGFM and of PGE2 into PGEM, were assessed by using the PGF2alpha, PGE2, PGEM, and PGFM EIA Kits from Cayman following the manufactur- 
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AND HPGD er's instructions. The intra-and interassay coefficients of variation were approximately 3%. In a final step, plates were read photometrically using the SpectraMax Plus384 Absorbance Microplate Reader (Bucher Biotec AG) set at 405 nm.
Protein Preparation and Western Blot
Transfected cells and tissue homogenates were prepared with NET-2 lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 0.05% NP-40) and protease inhibitor cocktail (10 ll/ml) mixed solution. Subsequently, tissue extracts were centrifuged at 10 000 3 g for 10 min at 48C. Proteins in the supernatant were disrupted by sonication (Vibra-Cell) at 75 W for 15 sec and solubilized in sample buffer (25 mmol/L Tris-Cl, pH 6.8, 1% SDS, 5% b-mercaptoethanol, 10% glycerol, 0.01% bromphenol blue). Protein concentration was measured by the Bradford assay with a SmartSpec Plus spectrophotometer. SDS-PAGE was performed on a 12% polyacrylamide gel (Bio-Rad) at 120 V. Afterwards, proteins were transferred onto methanol-activated polyvinylidene difluoride (Bio-Rad) membranes for 1 h at 100 V. Subsequently, the membranes were incubated for 1 h in 5% low-fat milk powder in 0.25% Tween-20 PBS (PBST), to block nonspecific binding. Membranes were then incubated overnight at 48C in 2.5 % low-fat milk powder in PBST containing a primary antibody. Afterwards, membranes were washed 3 times for 10 min in PBST at room temperature on a shaker and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room temperature. After subsequent washing 5 times for 10 min in PBST, signals were initiated by adding the Immun-Star WesternC Chemiluminescent Kit substrate (Bio-Rad) according to the manufacturer's protocol. The blots were visualized with the ChemiDoc XRSþ System and Image Lab. Software, both from Bio-Rad.
Because of the lack of canine cross-reacting antibodies, canine-specific guinea pig polyclonal affinity purified anti-PGFS (AKR1C3) and -HPGD, custom-made antibodies were generated (Eurogentec SA) using the following peptide sequences: DTLFATHPDYPFNDED, C-terminal amino acids 309-324 of the canine PGFS (AKR1C3) sequence with GenBank accession number NP_001012344, and HFQDYETTPFHAKTQ, C-terminal amino acids 252-266 of canine HPGD sequence with GenBank accession number AFF60303. The antibodies were used at 1:1000 and 1:50 dilutions for PGFS (AKR1C3) and HPGD, respectively. The synthetic peptides used for immunizations were applied as epitope-specific blocking peptides. Additional antibodies used were mouse monoclonal anti-EYFP (JL-8) from Clontech Laboratories (632380; dilution 1:1000) and monoclonal mouse anti-His from Invitrogen (R940-25; dilution 1:100); b-actin mouse monoclonal antibody (sc-69879; dilution 1:1000; Santa Cruz Biotechnology); secondary HRP goat anti-mouse IgG (W402B) from Promega (dilution 1:15 000); and anti-guinea pig IgG conjugated to HRP from Sigma (A5545; dilution 1:15 000).
For semiquantitation of PGFS (AKR1C3) and HPGD expression, Western blot membranes were reblotted with anti b-actin antibody as loading control. The optical density of bands was determined using ImageJ software. The values are presented as the ratio of PGFS (AKR1C3) and HPGD optical density corresponding to b-actin optical density.
Immunohistochemistry
Formalin-fixed, paraffin-embedded utero/placental and CL samples 2-3 lm thick were cut with a microtome and mounted on SuperFrost Plus microscope slides (Menzel-Gläser). The subsequent experimental procedure was according to our previously described protocol [6, 23] . Briefly, slides were deparaffinized in xylol, rehydrated in a graded ethanol series, and washed under running tap water for 5 min. Antigen retrieval was performed in 10 mM citrate buffer pH 6.0 at room temperature for 5 min followed by microwave irradiation in an oven run at 560 W for 15 min. Then, sections were cooled at room temperature for 20 min and washed under the running tap water for 5 min. Endogenous peroxidase activity was quenched by incubating the sections in 0.3% hydrogen peroxide in methanol for 30 min on a shaker. Afterwards, they were washed in IHC buffer/0.3% Triton X, pH 7.2-7.4 (0.8 mM Na 2 HPO 4 , 1.47 mM KH 2 PO 4 , 2.68 mM KCl, 137 mM NaCl for 5 min and incubated in 10% goat serum for 20 min at room temperature in order to block nonspecific binding. Thereafter, slides were overlaid with canine-specific, polyclonal, affinity-purified guinea pig anti-PGFS (AKR1C3) and anti-HPGD antibodies, the same as for Western blot analysis. Both antibodies were diluted 1:750 in IHC/0.3% Triton X buffer and incubated overnight at 48C. The following negative controls were used: slides omitting the primary antibody and slides incubated with preimmune guinea pig serum at the same dilution as the primary antibodies. After subsequent washing with IHC/0.3% Triton X buffer, tissue sections were incubated for 30 min at room temperature with biotinylated secondary goat anti-guinea pig antibodies at 1:100 dilution (Vector Laboratories). Signals were enhanced with the streptavidin-avidin-peroxidase Vectastain ABC kit (Vector Laboratories), for 30 min at room temperature and finally detected using the Liquid DABþ substrate kit (Dako Schweiz AG). Sections were counterstained with hematoxylin, washed under running tap water, dehydrated in a graded ethanol series, and embedded in Histokit (Assistant).
In Situ Hybridization
RT-PCR reactions with the following primers were performed to generate templates for subsequent cRNA probe synthesis: HPGD forward: 5 0 -GCC CTG GAT GAG CAG TTT G-3 0 , HPGD reverse: 5 0 -CCA CCT TCT CCT CCG TTT TG-3 0 . Length of the amplicons was 251 bp. The PCR products were separated on a 2% ethidium bromide-stained agarose gel, purified using the Qiaex II gel extraction system, and subcloned into the pGEM-T vector. Selected clones were control digested with NcoI and NotI restriction enzymes (New England Biolabs) and sent for sequencing (Microsynth). After linearizing plasmids with the respective restriction enzymes, NcoI for antisense cRNA (antisense probe) and NotI for the sense cRNA (sense probe), synthesis of digoxigenin (DIG)-labeled probes was performed with the DIG-RNA labeling kit from Roche Diagnostics. Dot-blot analysis of serial dilutions of DIG-labeled cRNA was performed on positively charged nylon membrane (Roche Diagnostics). For nonradioactive ISH, paraffin-embedded tissue sections were used. Utero/placental samples were cut with a microtome (sections 2-3 lm thick) and mounted on SuperFrost Plus microscope slides, dewaxed, rehydrated, digested with proteinase K (70 lg/ml; Sigma-Aldrich) for permeabilization, postfixed with 4% paraformaldehyde, and submitted to the ISH procedure following our previously described protocol [23] . The hybridization was overnight at 378C. The DIG-labeled cRNA was detected via alkaline phosphatase conjugated sheep anti-DIG Fab Fragments (Roche Diagnostics) used at 1:5000 dilution in 1% ovine serum according to the manufacturer's instructions. Signals were detected with the substrate 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (NBT/BCIP; Roche Diagnostics). 
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Statistics
Parametric one-way ANOVA followed by a Tukey-Kramer multiple comparisons posttest was used to determine the effect of time on luteal HPGD mRNA and utero/placental PGFS (AKR1C3) protein expression. Because of the uneven distribution of the data obtained for the utero/placental HPGD mRNA expression and the luteal HPGD protein expression, the Kruskal-Wallis test (a nonparametric ANOVA) followed by a Dunn multiple comparison test was performed in the event of P , 0.05. The numerical data are presented as the mean 6 SD. All tests were performed with the statistical software program GraphPad 3.06 (GraphPad Software).
RESULTS
Utero/Placental and Luteal Expression of PGFS (AKR1C3) Throughout Pregnancy
Canine PGFS (AKR1C3)-His and EYFP-tagged fusion proteins were overexpressed in Vero 2.2 cells. The expression of PGFS (AKR1C3)-EYFP protein was controlled under a fluorescence microscope to check for transfection efficiency (Fig. 1, A and B) . When high transfection efficiency was observed (at 24-48 h), cells were harvested and used in Western blot analysis to detect recombinant proteins using the anti-EYFP and anti-His antibodies (Fig. 1C) . The PGFS (AKR1C3)-EYFP protein was detected as a protein of approximately 64 kDa, whereas the PGFS (AKR1C3)-His displayed a molecular weight of approximately 34-36 kDa, thereby indicating the actual size of the canine PGFS (AKR1C3) protein cloned using the canine-specific cDNA sequence with GenBank number NM_001012344 (Fig. 1C) as a template. In a further step, Western blot analysis with the custom-made canine-specific anti-PGFS (AKR1C3) antibody was performed. The PGFS (AKR1C3)-His coupled protein was used as a positive control (Fig. 1D) . The apparent molecular size of the expressed protein was identical to that of the endogenous isoform expressed in the canine utero/placental compartments (Fig. 1D) . Nontransfected Vero 2.2 cells were used as negative controls; only a weak background signal was observed (Fig. 1D) . Blocking the PGFS (AKR1C3) antibody with epitope-specific blocking peptide significantly diminished the signal (Fig. 1E) .
The utero/placental expression of PGFS (AKR1C3) protein throughout pregnancy was strongly modulated (P , 0.01) and dependent upon the stages of pregnancy (Fig. 2A ). There were no or only weak signals observed on Western blots prior to implantation ( Fig. 2A) . This was probably attributable to the very low expression level observed at this time. Afterwards, during the postimplantation and midgestation periods of pregnancy, PGFS (AKR1C3) protein expression was strongly upregulated (P , 0.01) (Fig. 2A) . The signal intensity decreased at the time of the prepartum luteolysis (P , 0.01) (Fig. 2A) .
Only weak or no PGFS (AKR1C3) protein signals were observed in samples derived from luteal tissues (Fig. 2B) .
The utero/placental expression of PGFS (AKR1C3) was localized by IHC using the canine-specific anti-PGFS (AKR1C3) antibody. There were no or only very weak signals observed in the uterine samples preimplantation (not shown). Within the utero/placental units, PGFS (AKR1C3) was localized in the epithelial cells of the superficial uterine glands, the so-called glandular chambers (Fig. 3A) . Interestingly, no signals were observed in the deep uterine glands (Fig. 3B) . The placental signals were localized in the trophoblast cells (Fig. 3,  C and D) , mostly within the feto-maternal contact zone (Fig.  3D) . Weaker placental signals were observed at the time of prepartum luteolysis (not shown).
Spatiotemporal Expression of HPGD in Utero/Placental Compartments and CL Throughout Pregnancy
Following homology cloning, the predicted ORF of canine HPGD of 801 nucleotides encoding for a 267-amino-acid protein was sequenced and characterized. As revealed in the homology search against the GenBank database with the online-available BLAST software, the canine HPGD sequence displays a very high similarity for nucleotide (91%-95%) and protein sequences (94%-97%) with those of, e.g., horse (GenBank accession number NM_001081786), pig (GenBank accession number NM_001190248), cow (GenBank accession number NM_001034419), and human (GenBank accession number NM_000860). In the alignment against the canine genomic sequence, the HPGD has been localized to chromosome 25. The cloning and characterization of canine HPGD provided the basis for our subsequent investigations at the mRNA and protein levels.
The expression of HPGD mRNA was detected in all luteal and utero/placental samples investigated and demonstrated highly significant effects of time (P , 0.01; Fig. 4, A and B) . As for the utero/placental compartment, low expression was observed in the preimplantation uterus. Following placental formation, levels of HPGD mRNA increased significantly (P , 0.05), reaching the highest mRNA levels during the postimplantation period of pregnancy. The mRNA levels were numerically but nonsignificantly lower in midpregnancy (P . 0.05), and were significantly depressed (P , 0.05), reaching their lowest utero/placental levels, during prepartum luteolysis (Fig. 4A) .
Similarly, the luteal HPGD mRNA levels increased from the preimplantation stage of gestation to reach significantly higher values (P , 0.05) postimplantation. However, no significant changes were observed thereafter from midgestation through prepartum luteolysis (P . 0.05) (Fig. 4B) .
Applying the same experimental strategy, based on the cloned canine-specific HPGD sequence (GenBank accession number JQ407019), HPGD-His and -EYFP-tagged fusion proteins were produced in a heterologous system. The expression of HPGD-EYFP was visualized under the fluorescence microscope (Fig. 5, A and B) . Subsequently, after 24-48 h, cells were harvested and used in Western blot analysis for detection of fusion proteins (Fig. 5C ). The HPGD-EYFP was found as a protein of approximately 57 kDa; the molecular weight of HPGD-His was approximately 30 kDa, indicating the size of the cloned HPGD (Fig. 5C ). When the canine-specific anti-HPGD antibody was used, the molecular size of the expressed recombinant protein was identical to that of the endogenous isoform found in the luteal and utero/placental tissues (Fig. 5D) . The HPGD-His protein served as a positive control in these experiments. For the negative control, nontransfected Vero 2.2 cells were used, displaying a weak GRAM ET AL.
background staining (Fig. 5D) . The signal was significantly diminished when the anti-HPGD antibody was blocked with epitope-specific blocking peptide (Fig. 5E) .
Subsequently, the HPGD protein expression profiles were investigated by Western blot analysis (Fig. 6) . The utero/ placental expression was time dependent (P , 0.01). It was highest from the preimplantation until midgestation stages, then there was a significant decrease at prepartum luteolysis (P , 0.05). At the cellular level, and as determined by IHC, in the preimplantation group weaker uterine signals were observed in the surface epithelium and superficial endometrial glands (Fig.  7, A and B) . In contrast, strong immunohistochemical signals were observed in the deep uterine glands (Fig. 7B) . Following implantation, endometrial signals were localized to the superficial glandular epithelial cells, within the so-called glandular chambers (Fig. 7C) . Placental signals were localized in the trophoblast cells, especially those in the feto-maternal contact zone (Fig. 7D) . The intensity of IHC signals decreased during prepartum luteolysis (not shown). A similar signal distribution pattern was found at the mRNA level by ISH (Fig.  8) .
As for the luteal tissues, Western blot signals for HPGD expression were generally weaker (Fig. 6B) . Even though the signals tended to be stronger at the earlier luteal stages, when statistical analysis was applied, due mostly to the large individual variations, the luteal protein expression did not differ significantly over time (P . 0.05). The cellular signals were observed throughout pregnancy and were localized to the luteal cells (Fig. 7E) . However, as observed in the Western blot analysis, variability between individual animals was high.
Biochemical Activities of Canine PGFS (AKR1C3) and HPGD
In order to determine biochemical activities of the canine proteins towards their specific substrates, 1 lg of purified recombinant PGFS (AKR1C3)-His and HPGD-His proteins was used. For both enzymes, samples omitting recombinant proteins were run to check for possible background signals resulting from the assay. These were then subtracted from the signals obtained from enzymatic activity of the recombinant proteins. The only metabolic activity of PGFS (AKR1C3) was towards the conversion of PGH2 to PGF2alpha, revealing the highest conversion rate of 300.5 6 35 ng/ml with 30 lM PGH2 within 10 min; no activity towards PGE2 synthesis was found. The catabolic activity of the recombinant HPGD was confirmed towards both PGF2alpha and PGE2, revealing maximum values of 376.22 6 66.83 pg/ml PGFM and 490.33 6 106.53 pg/ml PGEM with 30 lM of the respective substrate within 10 min. The PGFS (AKR1C3) and HPGD activities were lacking in the absence of the respective cofactors (NADPH and NAD þ ). Detailed studies on enzyme kinetics are not within the focus of the present study.
DISCUSSION
Our demonstration of the bioactivity of the previously cloned [5] canine PGFS (AKR1C3) towards PGF2alpha synthesis using the recombinantly expressed protein confirms the bio-identity of the protein and precludes any concerns as regards homology with members of the aldo-keto reductase family. The generation, validation, and application of PGFS (AKR1C3) antibodies for the immunolocalization and quantitation of PGFS (AKR1C3) enzyme in luteal and utero-placental tissues demonstrated at the protein level a reduction in PGFS (AKR1C3) expression during prepartum luteolysis. These results agree with our prior report of a prepartum decrease in uterine PGFS (AKR1C3) message expression at that time [9] and suggest that mechanisms not involving increased PGFS (AKR1C3) may participate in the prepartum utero/placental 
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increase in PGF2a release. Considering the low uterine expression of PGFS (AKR1C3) prior to implantation, the observed localization of uterine expression of PGFS (AKR1C3) to the surface epithelial cells and the superficial glandular chambers after implantation suggests a role for that activity in canine placentation. The low level of PGFS (AKR1C3) protein expression observed in luteal tissue is in agreement with our previous conclusion that slow luteal regression in the dog is independent of locally produced PGF2alpha [5] and agrees with the low levels of PGF2alpha output observed in vitro in luteal tissue explants obtained from late-stage CL [10] .
That PGFS (AKR1C3) staining at the cellular level was localized to the fetal trophoblast cells, especially in the fetomaternal contact zone, strongly suggests potential roles for PGFS (AKR1C3) during the processes of decidualization, placental development, and trophoblast invasion. Our data on the PGF2alpha hydroxylation enzyme expression suggest that a decrease in HPGD in addition to the previously reported [9] increase in PTGS2 expression participates in the surge release of PGF2alpha by the prepartum uterus.
The successful molecular cloning, sequencing, and recombinant expression of canine HPGD reported herein and the validation of its bioactivity permitted the generation and validation of canine-specific anti-HPGD antibody. The data obtained from the subsequent examination of the expression and cellular localization of the native enzyme by IHC and ISH suggest that changes in HPGD expression during pregnancy affect the extent of PGF2alpha release by canine uteroplacental compartments. The findings that utero/placental HPGD expression was upregulated until midgestation, followed by a prepartum decrease, and that the cellular localization was the same as PGFS (AKR1C3), suggests that a dynamic and potential regulatory interrelationship exists among these entities. Increased HPGD expression observed in midpregnancy could explain the low peripheral PGF2alpha levels at a time of increased PGFS (AKR1C3) expression [9] , whereas the observed decrease in HPGD expression at prepartum may be involved in the luteolytic surge in PGF2alpha at a time when PGFS (AKR1C3) is reduced. It is possible that the observed increases in HPGD during prepartum luteolysis in these dogs were responses to ongoing declines in P4. In humans, placental HPGD mRNA expression and activity is elevated by P4 analogue administration [24] , and HPGD activities in human syncytiotrophoblast and chorionic trophoblast in vitro [24] were reduced by treatment with the selective P4-receptor blockers RU486 and onapristone. Furthermore, preliminary study in our laboratory suggests this is true for the dog as well; the utero-placental HPGD expression in midpregnant dogs was significantly reduced at the messenger level in response to treatment with the antiprogestin aglepristone (Kowalewski, 2013, unpublished results) .
In contrast to the strongly time-dependent utero/placental HPGD expression, the luteal protein expression varied strongly among the samples and groups. Even if the protein levels tended to be higher at the beginning of the CL phase, they did not change significantly throughout gestation. Especially because the luteal HPGD mRNA levels displayed a timerelated expression pattern, further investigations, possibly involving larger experimental groups, are needed in order to draw any final conclusion.
The results to date as regards the mechanism of PGF2alpha release precipitating canine parturition suggest that fetal or maternal factors regulating PTGS2 expression as a rate-limiting step both during pregnancy and during prepartum luteolysis, as well as the possible alternative pathways of PGF2alpha synthesis, as discussed recently [1, 9] , merit further study.
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